Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138400 | 0.91 | EPHX1 (0.52) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL27163256 | 0.91 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 | |
| SCHEMBL14348333 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 | |
| SCHEMBL22962006 | 0.85 | EPHX1 (0.57) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 | |
| SCHEMBL1503851 | 0.80 | EPHX2 (0.41) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 | |
| SCHEMBL6857874 | 0.78 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 | |
| SCHEMBL19500088 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 | |
| SCHEMBL15294792 | 0.78 | EGLN1 (0.47) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL13700916 | 0.76 | SSTR4 (0.40) | — | |
| SCHEMBL10157163 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465590-B2 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-11-11 | — | — | US | disclosed |
| US-12404284-B2 | Spirocyclic inhibitors of hepatitis B virus | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-09-02 | — | — | US | disclosed |
| CN-119409710-A | Oxamide substituted hepatitis b virus tricyclic inhibitors | 圣拉斐尔医院有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4494709-A2 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2025-01-22 | — | — | EP | disclosed |
| CN-114555608-B | Oxamide substituted hepatitis b virus tricyclic inhibitors | 圣拉斐尔医院有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4103567-B1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-10-23 | — | — | EP | disclosed |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-18 | — | — | US | disclosed |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-18 | — | — | US | disclosed |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-18 | — | — | US | disclosed |
| CN-115551870-A | Spirocyclic inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-114555608-A | Oxamide substituted tricyclic inhibitors of hepatitis b virus | 分子遗传国家研究所(INGM) | 2022-05-27 | — | — | CN | disclosed |
| EP-3985010-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2022-04-20 | — | — | EP | disclosed |
| EP-3985010-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2022-04-20 | — | — | EP | disclosed |
| EP-3972979-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Antios Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021160617-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160617-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020234483-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020234483-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) | 2020-11-26 | — | — | WO | disclosed |
| EP-3741762-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741762-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465590-B2 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | OAT, SLC10A1, OTC | SMN1; SMN2 4849/4885NPC1 474/4885RAB9A 3979/4885 |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, NR1H4 | SMN1; SMN2 4876/4885NPC1 23/4885RAB9A 2556/4885 |
| US-12404284-B2 | Spirocyclic inhibitors of hepatitis B virus | HAVCR2, SLC10A1, NR1H4 | SMN1; SMN2 4876/4885NPC1 23/4885RAB9A 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.